Literature DB >> 16422874

Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction.

Chris McMahon1.   

Abstract

OBJECTIVE: To assess and compare the efficacy of on-demand tadalafil and daily tadalafil in the treatment of erectile dysfunction.
MATERIALS AND METHODS: A total of 145 men with a mean age of 57.3 years (range 19-82 years) and mild to severe erectile dysfunction of various etiologies were randomized to receive on-demand tadalafil (20 mg) or daily tadalafil (10 mg) taken without food or alcohol restrictions in a trial lasting 26 weeks. The three primary outcome measures were changes from baseline in the erectile function domain of the International Index of Erectile Function (IIEF), the proportion of "yes" responses to questions 2 and 3 of the Sexual Encounter Profile (SEP). Additional efficacy instruments included a Global Assessment Question administered at completion of the study.
RESULTS: Compared with baseline, on-demand and daily tadalafil enhanced all efficacy outcomes. Patients receiving on-demand tadalafil (20 mg) and daily tadalafil (10 mg) experienced a significant mean improvement of 8.3 and 11.9, respectively, in the erectile function domain of the IIEF from baseline (P < 0.001). The mean change from baseline was significantly higher for daily dosed tadalafil than for on-demand tadalafil (P < 0.05). Sexual intercourse was successfully completed (SEP3) in 69% and 84% of patients taking on-demand tadalafil and daily tadalafil, respectively, compared with 30% at baseline (P < 0.001). Successful completion of sexual intercourse was statistically higher for daily tadalafil than for on-demand tadalafil (P < 0.05). Treatment with on-demand tadalafil or daily tadalafil was well tolerated, and headaches, facial flushing, and dyspepsia were the most frequently observed adverse events.
CONCLUSION: Tadalafil was effective and well tolerated in this patient population. Treatment with daily tadalafil was associated with a significantly higher IIEF erectile function domain score and completion of successful intercourse compared with on-demand tadalafil.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16422874     DOI: 10.1111/j.1743-6109.2005.20360.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  24 in total

Review 1.  Daily dosing of PDE5 inhibitors: where does it fit in?

Authors:  King Chien Joe Lee; Gerald B Brock
Journal:  Curr Urol Rep       Date:  2013-08       Impact factor: 3.092

Review 2.  [Conservative therapy of erectile dysfunction].

Authors:  M Trottmann; J Marcon; S Pompe; D Strobach; A J Becker; C G Stief
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

Review 3.  Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails.

Authors:  Mary Lee; Roohollah Sharifi
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

Review 4.  Erectile dysfunction and cardiovascular disease: efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions.

Authors:  Ajay Nehra
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

5.  Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms.

Authors:  H Choi; J-H Kim; J-S Shim; J Y Park; S H Kang; D G Moon; J Cheon; J G Lee; J J Kim; J-H Bae
Journal:  Int J Impot Res       Date:  2014-07-03       Impact factor: 2.896

6.  Optimizing postoperative sexual function after radical prostatectomy.

Authors:  Manuela Tutolo; Alberto Briganti; Nazareno Suardi; Andrea Gallina; Firas Abdollah; Umberto Capitanio; Marco Bianchi; Niccolò Passoni; Alessandro Nini; Nicola Fossati; Patrizio Rigatti; Francesco Montorsi
Journal:  Ther Adv Urol       Date:  2012-12

7.  Impact of phosphodiesterase type 5 inhibitors on endothelial function.

Authors:  Patrick E Teloken; John P Mulhall
Journal:  Rev Urol       Date:  2008

Review 8.  [Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].

Authors:  H Porst; K Hell-Momeni; H Büttner
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

9.  Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives.

Authors:  Pierre Costa; Thierry Grivel; Naji Gehchan
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

Review 10.  Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?

Authors:  Yoram Vardi
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.